+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Making the Best of Available Options for Optimal Sarcoma Treatment



Making the Best of Available Options for Optimal Sarcoma Treatment



Oncology 95(Suppl. 1): 11-20



For 35 years options for treating advanced soft tissue sarcoma (STS) were limited to doxorubicin, dacarbazine and ifosfamide. In 2007, trabectedin was approved. Since then, several other agents have become available and many more are in development, ushering in a new era in disease management. Considerable scope exists for improving outcomes of advanced STS through better trial design and improved patient care in everyday practice. After anthracycline failure, there are a range of treatment options and, increasingly, the choice of therapy is histology driven. Introduction of newer agents and optimising use of established agents such as trabectedin has led to an increase in overall survival of advanced STS patients. Optimising treatment with trabectedin is being achieved through more extensive experience in drug management, mainly associated with use in earlier lines and uninterrupted use until disease progression. Identification by next-generation sequencing of a significant proportion of cases of actionable mutations among patients with advanced STS suggests a move towards matched therapy in future. As the armamentarium of active agents in advanced sarcoma increases, so too will the challenge of selecting the right drug for the right patient at the right time, in accordance with the patient's lifestyle and wishes.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066010865

Download citation: RISBibTeXText

PMID: 30554197

DOI: 10.1159/000494861


Related references

More options, more considerations: how new treatment options influence clinical decision making. Journal of Thoracic Disease 8(10): E1408-E1409, 2016

Rationale and Options for Choosing an Optimal Closure Technique for Primary Midsagittal Osteochondrotomy of the Sternum. Part 3: Technical Decision Making Based on the Practice of Patient- Appropriate Medicine. Critical Reviews in Biomedical Engineering 47(1): 59-99, 2019

Treatment of seriously compromised teeth: decision- making criteria and treatment options. Minerva Stomatologica 62(9): 321-333, 2013

Ewing's sarcoma: standard and experimental treatment options. Current Treatment Options in Oncology 10(1-2): 126-140, 2009

Review of treatment options for vaccine-associated feline sarcoma. Journal of the American Veterinary Medical Association 213(10): 1426-1427, 1998

Kaposi's sarcoma in HIV-infected patients: treatment options. HIV Medicine 1(3): 137-142, 2000

HIV protease inhibitors as new treatment options for Kaposi's sarcoma. Drug Resistance Updates 6(4): 173-181, 2003

HIV plus hepatitis C or Kaposi sarcoma. Treatment options in coinfection. Mmw Fortschritte der Medizin 142(Suppl. 1): 58-59, 2000

Kaposi's sarcoma: case report and treatment options. Medical Journal of Malaysia 66(4): 383-384, 2011

Treatment Options in Primary Ewings Sarcoma of the Spine. Neurosurgery 32(3): 480-481, 1993

Treatment of Metastatic, Refractory Alveolar Soft Part Sarcoma: Case Reports and Literature Review of Treatment Options in the Era of Targeted Therapy. Journal of Pediatric Hematology/Oncology 38(5): E169-E172, 2016

Pregnancy-associated breast cancer: optimal treatment options. International Journal of Women's Health 6: 935-943, 2014

Pyelonephritis in pregnancy: treatment options for optimal outcomes. Drugs 61(14): 2087-2096, 2001

Current and future options in the management and treatment of uterine sarcoma. Therapeutic Advances in Medical Oncology 6(1): 21-28, 2014

Etiology, pathogenesis and treatment options in Kaposi's sarcoma of HIV infection. Przeglad Epidemiologiczny 55(Suppl. 3): 129-135, 2001